Before diving into the nomenclature shift, it is crucial to understand what Vhm-314 is and why it generated so much attention.
Vhm-314 was initially presented as a synthetic nootropic compound—a member of the racetam family or a structurally unique cognitive enhancer, depending on the source. Early preclinical studies suggested that Vhm-314 exhibited potential for:
However, Vhm-314 never received full FDA approval or entered Phase III clinical trials under that name. It existed primarily as a research chemical, sold by specialty laboratories to academic and private researchers. Vhm-314 Change Name
Once the alias is set, force a propagation event to update downstream nodes.
vhm-314 --propagate --force
After months of speculation on forums like Reddit’s r/Nootropics and Longecity, the official new designation for Vhm-314 has been confirmed by the primary Chinese and U.S.-based synthesis labs. Before diving into the nomenclature shift, it is
The new name is: N-Methyl-Cyclohexyl-Noopept Analog (NMCNA-7).
In some catalogs, it is simply listed as "Compound NMCNA-7" or "NMCNA-7 (formerly Vhm-314)." However, Vhm-314 never received full FDA approval or
A secondary trade name—"Cognilan-7"—has been registered for a proprietary blend containing NMCNA-7, but the pure research chemical is now universally referred to as NMCNA-7 in peer-reviewed literature preprints.
⚠️ Important: Vendors still using “Vhm-314” after March 2025 are likely selling old, unstable stock or potentially counterfeit material. Always verify the new name NMCNA-7 on the certificate of analysis (COA).
Before initiating the change, verify the current status of the entity. Ensure no active processes are writing to the object.
# Example CLI check
vhm-cli --status 314 --target [OLD_NAME]